The Issue

Over 6 million people in North America suffer from kidney or heart failure.
In Quebec alone, there are 160,000 individuals affected by these diseases.
0 dialyses

per week

Patients undergo a 5-hour dialysis session three times a week.

The average annual cost related to kidney failure in North America is $60 billion, due to these patients having the highest hospitalization rate.

The Medical Challenge

Overcoming Kidney Failure

Kidney failure is a critical health issue that affects millions of people in North America. This condition places a significant burden on patients as they must regularly undergo dialysis sessions to maintain their electrolyte balance and eliminate toxins from their blood.

Indeed, patients with severe chronic kidney failure often find themselves frequently visiting the hospital for dialysis, often up to three times a week.

The primary challenge these patients face arises when they return home. Once out of the hospital, these patients have no reliable way of knowing if they are starting to accumulate pulmonary fluid. The problem lies in the fact that the accumulation of water in the lungs, known as pulmonary edema, doesn’t produce obvious symptoms in its early stages. Consequently, patients are generally unaware of this buildup until it becomes severe and leads to potentially life-threatening complications. The lack of predictable symptoms makes early detection of pulmonary edema challenging. Currently, existing monitoring methods are not sufficiently accurate or practical to enable patients to detect this intrapulmonary fluid accumulation between dialysis sessions. Hospital visits for X-rays or MRIs are often necessary, but they are costly and cannot provide regular monitoring.

Medical Innovation

At Displaid, we offer a non-invasive medical imaging solution in the form of a thoracic belt that the patient wears once a day for about a minute. Thanks to this innovative device, coupled with our powerful artificial intelligence algorithm, we can detect the presence of pulmonary fluid in its asymptomatic phase. This technological advancement allows both the patient and their physician to closely monitor the progression of pulmonary fluid.

The remote accessibility of this information for the patient’s doctor is a significant asset. By receiving personalized real-time alerts, the physician can proactively adjust the patient’s treatment or medication, preventing complications. This greatly reduces the need for hospitalizations and decreases the frequency of medical check-ups.


R&D team focused on innovation

At Displaid, our research and development team is constantly looking for improvements that can be brought to the healthcare environment.

Our multidisciplinary engineering team provides a high level of expertise and understanding of all the new projects we undertake.